Abstract
In the current study, novel paclitaxel-loaded cross-linked hyaluronan nanoparticles were engineered for the local delivery of paclitaxel as a prototype drug for cancer therapy. The nanoparticles were prepared using a desolvation method with polymer cross-linking. In vitro cytotoxicity studies demonstrated that less than 75% of the MDA-MB-231 and ZR-75-1 breast cancer cells were viable after 2-day exposure to paclitaxel-loaded hyaluronan nanoparticles or free paclitaxel, regardless of the dose. These results suggest that hyaluronan nanoparticles maintain the pharmacological activity of paclitaxel and efficiently deliver it to the cells. Furthermore, in vivo administration of the drug-loaded nanoparticles via direct intratumoral injection to 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumor in female rats was studied. The paclitaxel-loaded nanoparticles treated group showed effective inhibition of tumor growth in all treated rats. Interestingly, there was one case of complete remission of tumor nodule and two cases of persistent reduction of tumor size that was observed on subsequent days. In the case of free paclitaxel-treated group, the mean tumor volume increased almost linearly (R 2 = 0.93) with time to a size that was 4.9-fold larger than the baseline volume at 57 days post-drug administration. Intratumoral administration of paclitaxel-loaded hyaluronan nanoparticles could be a promising treatment modality for solid mammary tumors.
References
Deurloo MJ, Kop W, van Tellingen O, Bartelink H, Begg AC. Intratumoural administration of cisplatin in slow-release devices: II. Pharmacokinetics and intratumoural distribution. Cancer Chemother Pharmacol 1991;27 5:347–53.
Aigner KR. Intra-arterial infusion: overview and novel approaches. Semin Surg Oncol 1998;14 3:248–53.
Lee JD, Yang WI, Lee MG. Effective local control of malignant melanoma by intratumoural injection of a beta-emitting radionuclide. Eur J Nucl Med Mol Imaging 2002;29 2:221–30.
Zhang X, Jackson JK, Wong W. Development of biodegradable polymeric paste formulations for taxol: an in vitro and in vivo study. Inter J Pharm 1996;137 2:199–208.
Dhanikula AB, Panchagnula R. Development and characterization of biodegradable chitosan films for local delivery of paclitaxel. AAPS J 2004;6 3:e 27.
Ho EA, Vassileva V, Allen C, Piquette-Miller M. In vitro and in vivo characterization of a novel biocompatible polymer–lipid implants system for the sustained delivery of paclitaxel. J Cont Rel 2005;104 1:181–91.
Ramaswamy M, Zhang X, Burt HM, Wasan KM. Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J Pharm Sci 1997;86 4:460–4.
Luo Y, Prestwich GD. Synthesis and selective cytotoxicity of a hyaluronic acid–antitumor bioconjugate. Bioconjug Chem 1999;10 5:755–63.
Lokeshwar VB, Selzer MG. Differences in hyaluronic acid-mediated functions and signaling in arterial, microvessel, and vein-derived human endothelial cells. J Biol Chem 2000;275 36:27641–9.
Obara K, Ishihara M, Ozeki Y. Controlled release of paclitaxel from photocrosslinked chitosan hydrogels and its subsequent effect on subcutaneous tumor growth in mice. J Control Release 2005;110 1:79–89.
Hardingham T, Fosang A. Proteoglycans: many forms and many functions. FASEB J 1992;6 3:861–70.
Hoare K, Savani RC, Wang C, Yang B, Turley EA. Identification of hyaluronan binding proteins using a biotinylated hyaluronan probe. Connect Tissue Res 1993;30 2:117–26.
Turley EA, Belch AJ, Poppema AJ, Pilarski LM. Expression and function of a receptor for hyaluronan-mediated motility on normal and malignant lymphocytes-B. Blood 1993;81 2:446–53.
Vazquez E, Dewitt DM, Hammond PT, Lynn DM. Construction of hydrolytically-degradable thin films via layer-by-layer deposition of degradable polyelectrolytes. J Am Chem Soc 2002;124 47:13992–3.
Benkirane-Jessel N, Schwinte P, Falvey P. Build-up of polypeptide multilayer coatings with anti-inflammatory properties based on the embedding of piroxicam–cyclodextrin complexes. Adv Funct Mater 2004;14 2:174–82.
Guyomard A, Nysten B, Muller G, Glinel K. Loading and release of small hydrophobic molecules in multilayer films based on amphiphilic polysaccharides. Langmuir 2006;22 5:2281–7.
Berg MC, Zhai L, Cohen RE, Rubner MF. Controlled drug release from porous polyelectrolyte multilayers. Biomacromolecules 2006;7 1:357–64.
Massey PJ, Chen TT, Caudle MR. Biphasic steroidogenic effects of taxol and cremophor EL. Endocrine 1994;2 10:891–7.
Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane). Cancer 2003;98 4:822–31.
Shu XZ, Liu Y, Palumbo FS, Prestwich GD. Disulfide-crosslinked hyaluronan-gelatin hydrogel films: a covalent mimic of the extracellular matrix for in vitro cell growth. Biomaterials 2003;24 21:3825–34.
Barichello JM, Morishita M, Takayama K, Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm 1999;25 4:471–6.
Isik Gonul I, Akyurek N, Dursun A, Kupeli B. Relationship of Ki67, TP53, MDM-2 and BCL-2 expressions with WHO 1973 and WHO/ISUP grades, tumor category and overall patient survival in urothelial tumors of the bladder. Pathol Res Pract 2008;204 10:707–17.
Pouyani T, Prestwich GD. Functionalized derivatives of hyaluronic acid oligosaccharides: drug carriers and novel biomaterials. Bioconjug Chem 1994;5 4:339–47.
Prestwich GD, Marecak DM, Marecek JF, Vercruysse KP, Ziebell MR. Controlled chemical modification of hyaluronic acid: synthesis, applications, and biodegradation of hydrazide derivatives. J Controlled Release 1998;53 1–3:93–103.
Vercruysse KP, Prestwich GD. Hyaluronate derivatives in drug delivery. Crit Rev Ther 1998;15 5:513–55.
Jaracz S, Chen J, Kuznetsova LV, Ojima I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem 2005;13 17:5043–54.
Liao YH, Jones SA, Forbes B, Martin GP, Brown MB. Hyaluronan: pharmaceutical characterization and drug delivery. Drug Delivery 2005;12 6:327–42.
Yadav AK, Mishra P, Agrawal GP. An insight on hyaluronic acid in drug targeting and drug delivery. J Drug Targ 2008;16:91–107.
Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415–27.
Zamboni WC. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 2005;11 23:8230–4.
Alonso MJ, Cohen S, Park TG, Gupta RK, Siber GR, Langer R. Determinants of release rate of tetanus vaccine from polyester microspheres. Pharm Res 1993;10 7:945–53.
Culty M, O’Mara TE, Underhill CB, Yeager H Jr, Swartz RP. Hyaluronan receptor (CD44) expression and function in human peripheral blood monocytes and alveolar macrophages. J Leukoc Biol 1994;56 5:605–11.
Herrera-Gayol A, Jothy S. Effects of hyaluronan on the invasive properties of human breast cancer cells in vitro. Int J Exp Pathol 2001;82 3:193–200.
Jain RK. Delivery of molecular medicine to solid tumors. Science 1996;271 5252:1079–80.
Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Inv 2002;110 4:475–82.
Harper E, Dang W, Lapidus RG, Garver RI. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local–regional therapy of lung cancer tumor nodules in mice. Clin Cancer Res 1999;5 12:4242–8.
Acknowledgment
This research was supported by grant no. 85-001-19-IRG to AMA from the American Cancer Society.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Al-Ghananeem, A.M., Malkawi, A.H., Muammer, Y.M. et al. Intratumoral Delivery of Paclitaxel in Solid Tumor from Biodegradable Hyaluronan Nanoparticle Formulations. AAPS PharmSciTech 10, 410–417 (2009). https://doi.org/10.1208/s12249-009-9222-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-009-9222-5